The recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) is undergoing clinical trials for prophylaxis and on-demand treatment of haemophilia B patients. The aim of this study was to investigate the pharmacokinetics, whole-body and knee joint distribution of rIX-FP following intravenous administration to rats, compared with a marketed, non-fused rFIX and recombinant human albumin. 
t r a c t a r t i c l e i n f o Introduction
Factor IX (FIX) is the zymogen of a serine protease that circulates in plasma at an average concentration of 5 μg/ml [1] . Activated FIX (FIXa) is an integral part of the tenase enzyme complex activating factor X, ultimately leading to blood coagulation [2, 3] . FIX-replacement therapy, using recombinant (rFIX) or plasma-derived (pdFIX) FIX is a safe and efficacious treatment approach to reduce bleeding rates among haemophilia B patients, while limiting haemarthrosis and arthropathy (potential causes of disability) [4] . Unfortunately, the relatively short terminal half-life of FIX of approximately 18-34 hours, necessitates frequent infusions every 2 or 3 days to maintain FIX clotting activity above 1% and to prevent spontaneous bleeding [5, 6] .
To improve therapeutic compliance and convenience, a novel recombinant fusion protein linking coagulation factor IX with albumin via a cleavable peptide linker (rIX-FP) has been designed to prolong the circulation time of FIX significantly; thus, improving its pharmacokinetic profile while maintaining its efficacy [7] [8] [9] . Understanding the tissue distribution of this novel coagulation factor construct is important to ensure that it reaches those areas necessary for maximum haemostatic efficacy. However, there is limited information available on the tissue distribution of FIX (rFIX/pdFIX) following intravenous administration and how fusion with albumin, as in the case of rIX-FP, may affect it. Therefore, this study aimed to investigate the pharmacokinetics and whole-body distribution of rIX-FP following intravenous administration of radiolabeled rIX-FP to rats, compared with a marketed, non-fused rFIX and recombinant human albumin, with particular focus on the bone-joint distribution profile. H-blood standards from which tissue concentrations of radioactivity were determined (nCi/g). Percentage total dose/tissue was also determined. Additionally, one hind limb from each animal was used for separate sectioning and a more detailed analysis of the knee joint.
Material and Methods

Radiolabelling
Quantitative Radiochemical and Chromatographic Analysis
Liquid scintillation counting (LSC) was used to determine the radioactivity level (disintegrations/minute) of the dose formulation, plasma, urine, faeces, and cage wash using a Packard 2300TR liquid scintillation analyser (PerkinElmer, Waltham, MA, USA) with automatic external standard quench correction and Ultima Gold XR scintillation fluid (PerkinElmer). Proportions of radioactivity in purified 3 H-labeled protein solutions, plasma and urine samples were determined by highperformance liquid chromatography (HPLC; Agilent 1100 HPLC system with ultraviolet detection at 280 nm) using a Phenomenex BIOSEP SEC 2000 size exclusion column (300 × 7.8 mm; mobile phase 100 mM sodium phosphate or 0.1 M phosphate buffer for protein solutions and body fluids, respectively). FIX antigen levels were also measured to confirm the presence of rIX-FP in tissues. 
Results
Characterisation
Analysis of Circulating Radioactivity and Pharmacokinetics
Plasma analysis confirmed the mean dose levels of~400 μCi/kg in each treatment group: Table S1 and Fig. S2 (a-c), respectively. Levels of intact protein recovered in plasma are shown in Table 1 and Fig. 1a .
]-rIX-FP (peak at~7 minutes) was the major component in plasma, accounting for~100% of all radioactivity up to 8 hours post-dosing (see Table 1 ). At 24 hours, this declined to 73.0%, with the remaining radioactivity composed of two peaks that co-chromatographed with albumin (at~8.5 minutes) and a low-molecular-weight (LMW) component (at 13.4 minutes), and represented 16.5% and 3.7% of the total radioactivity, respectively (Table S1 and (Table 1) . (Fig. 1a) . (Table 1) . This declined to 44.3% at 24 hours post-dose, with the majority of the remaining radioactivity (10.5%) associated with a LMW component (Table S1 and Fig. S2b) . (Fig. 1a) .
]-albumin was detected in plasma as a single peak at~8.5 minutes (Fig. S2c) . Up to 3 hours, all radioactivity measured was attributed to intact protein (Table 1) . From 8 to 240 hours, a second LMW peak appeared at 13 minutes (Table S1 and Fig. S2c) (Fig. 1a ). Comparison of the tissue radioactivity over time indicated that peak radioactivity concentrations generally occurred at 3−8 hours postdose, except in the adrenal gland and spleen, where they occurred at 0.25 hours and declined thereafter ( Fig. 2 and Fig. S3 ). Levels in spleen, lung, and liver remained approximately constant at 0.25-8 hours postdose. The longest radioactivity retention was in bone endosteum. Comparable levels were only detected up to 24 hours in other tissues (Fig. 2) . Levels in the kidney, whose concentrations over time are illustrated in Fig. 1b , increased up to 8 hours post-dose, whereas concentrations in the liver remained steady up to 3 hours and decreased thereafter (Fig. 1c) .
The timecourse of radioactivity concentrations observed along the gastrointestinal (GI) tract is listed in Table S2 . As can be seen, peak concentrations of [ 3 H]-rlX-FP in the small (350.0 nCi/g) and large (69.2 nCi/g) intestines occurred at 3−8 hours, whereas the caecum level remained below the limit of quantification, indicating reabsorption or re-use of radiolabeled material during its GI passage. In addition to autoradiographic tissue analysis, FIX antigen levels were determined in homogenized tissue samples following intravenous dosing of rIX-FP to rats. Preliminary data could confirm that the radioactive signals corresponded to the rIX-FP protein (Fig. S4) . (Fig. 1b,c) . Additionally, concentrations up to 5,870.0 nCi/g were detected in bladder contents, while concentrations within the small intestine, large intestine, and caecum contents remained b 178.0 nCi/g. However, in contrast to [ 3 H]-rIX-FP treatment, radioactivity was detectable within caecum contents, peaking at 128.0 nCi/g at 24 hours (Table S2) . in the periodontal membrane, tooth pulp, and bulbo-urethral gland (maximum levels 4,070.0−4,650.0 nCi/g); followed by the lungs, kidney, and bone endosteum (2,340.0−3,400.0 nCi/g) (Fig. 3) . High radioactivity concentrations were also observed in other highly vascularised tissues [nasal and caecum mucosa, myocardium, stomach wall, aorta (1,230.0−1,930.0 nCi/g)], as well as the epididymis, testes, lymph nodes, harderian glands, and bone periosteum (1,040.0−1,530.0 nCi/g).
Following [ 3 H]-albumin treatment, maximum concentrations
were generally reached at 3 hours post-dose. By 72 hours, radioactivity concentrations of all tissues had declined markedly with the longest tissue retention seen for the bone periosteum at 240 hours (data not shown). High levels of radioactivity were detected in the kidney, particularly the medulla region, which reached peak levels after 3 hours, slightly earlier than that of (Fig. 1c) . Concentrations within small intestine contents reached a maximum of 492.0 nCi/g at 1 hour post-dose. In comparison, large intestine and caecum contents displayed maximum concentrations of only 52.3 and 96.7 nCi/g, respectively, again indicating some reabsorption of radioactivity (Table S2) .
Total Dose Per Tissue In addition to the tissue concentrations of radioactivity, the total dose of radioactivity per tissue was determined and indicated that the liver received the highest total dose of [ 3 H]-rlX-FP, followed by muscle, kidney, lungs, and bone marrow (Fig. 4a) . (Fig. 4b) . However, at 24 hours post-dose, the levels of [ (Fig. 4c) . Overall, 73.3% of the dose could be detected within muscle at 8 hours. Levels in muscle, intestinal mucosa, skin, and lymph nodes were higher at 24 than 0.25 hours.
Knee-joint Distribution Fig. S5 includes the corresponding radioactivity concentrations determined for knee joint tissues. The data show that the highest radioactivity concentrations occurred in the calcified cartilage of the growth plate (5, 190 .0 nCi/g), followed by the bone endosteum (3, 440 .0 nCi/g), bone marrow (2, 200 .0 nCi/g), synovial space (709.0 nCi/g) and bone periosteum (515.0 nCi/g). Compact bone of the femur, fibula, and tibia, epiphysial plate and meniscus displayed low levels throughout. As can be seen in Fig. 5 , maximum concentrations occurred at 8 hours, except in the periosteum, which peaked at 3 hours, and in the bone endosteum, which peaked at 120 hours and exhibited the longest retention of radioactivity. .0 nCi/g), with peak levels at 3 hours post-dose, followed by the calcified cartilage (1,590.0 nCi/g), bone endosteum (814.0 nCi/g), and bone marrow (576.0 nCi/g), which peaked at 0.25 hours post-dosing (Fig. 5and Fig. S5 ).
Discussion
This study aimed to define further the in vivo characteristics of rIX-FP, which is currently undergoing clinical trials. Direct comparison with a currently available rFIX product, which has been approved for clinical use since 1997 [12, 13] , enabled an investigation of the influence of albumin fusion on the tissue distribution profile of rFIX.
Plasma Kinetics and Elimination
Importantly, [
3 H]-rIX-FP had a prolonged plasma terminal half-life compared with [ sites, such as the serine protease inhibitor antithrombin III (ATIII), on endothelial cells of the liver [14, 15] or specific low-density lipoprotein elimination pathways [18, 19] .
Similarly [14, 15] . The same studies also reported accumulation of radioactivity in the kidneys. The radioactivity levels in both the liver and kidney rapidly declined after [ 3 H]-rFIX dosing, which agrees with studies that reported no accumulation of mouse rFIX in these organs [20] . Similarly, there was no retention or accumulation of radioactivity following [ 3 H]-rIX-FP or [
